胰岛素皮下持续输注对初诊2型糖尿病患者胰岛功能及炎症因子的影响

Effects of Continuous Subcutaneous Insulin Infusion on Pancreatic Islet Function and Inflammatory Factors in Newly Diagnosed Type 2 Diabetes Mellitus

目的:观察胰岛素泵即胰岛素皮下持续输注(CSⅡ)对初诊2型糖尿病(T2DM)患者胰岛功能及炎症因子的影响。方法:选取2017年1月-2018年6月本院收治的初诊T2DM患者72例。根据入院先后顺序将其分为CSⅡ组和胰岛素多次皮下注射(MSII)组,各36例。CSⅡ组给予CSⅡ治疗,MSII组给予MSII治疗,均治疗2周。比较两组治疗前后的血糖情况(FPG、2 h PG及HbA1c)、胰岛β功能指标(FINS、HOMA-β、HOMA-IR)、炎症反应指标(CRP、IL-6及TNF-α)、胰岛素用量、血糖达标时间及低血糖发生次数。结果:治疗后,CSⅡ组FPG、2 h PG、HbA1c、HOMA-IR、CRP、IL-6及TNF-α水平均低于治疗前及MSII组,比较差异均有统计学意义(P<0.05);CSⅡ组FINS、HOMA-β水平均高于治疗前及MSII组,比较差异均有统计学意义(P<0.05);CSⅡ组胰岛素用量、血糖达标时间及低血糖发生次数均少于MSII组,比较差异均有统计学意义(P<0.05)。结论:CSⅡ能有效改善初诊T2DM患者胰岛β功能及炎性反应,有利于控制血糖水平,延缓病情进展,故可作为初诊T2DM的主要治疗方法。

Objective:To observe the effect of continuous subcutaneous insulin infusion(CSⅡ)on pancreatic islet function and inflammatory factors in newly diagnosed type 2 diabetes mellitus(T2DM). Method:A total of 72 newly diagnosed patients with T2DM in our hospital from January 2017 to June 2018 were selected.According to the order of admission,they were divided into CSⅡ group and MSII group,36 cases in each group.CSⅡ group was treated with CSⅡ,and MSII group was treated with MSII,they were treated for 2 weeks.The blood glucose(FPG,2 h PG and HbA1c),pancreatic islet β function(FINS,HOMA-β,HOMAIR),inflammatory response index(CRP,IL-6 and TNF-α)before and after treatment,and insulin dosage,time of blood sugar reaching the standard and frequency of hypoglycemia between two groups were compared. Result:After treatment,the levels of FPG,2 h PG,HbA1 c,HOMA-IR,CRP,IL-6 and TNF-α in CSⅡ group were lower than those of before treatment and MSII group,the differences were statistically significant(P<0.05).The levels of FINS and HOMA-β in CSⅡ group were higher than those of before treatment and MSII group,the differences were statistically significant(P<0.05).The insulin dosage,time of blood sugar reaching the standard and frequency of hypoglycemia in CSⅡ group were less than those of MSII group,the differences were statistically significant(P<0.05).Conclusion:CSⅡ can effectively improve the pancreatic islet β function and inflammatory response of newly diagnosed T2DM patients.It is beneficial to control the level of blood sugar and delay the progression of the disease.Therefore,it can be used as the main treatment method for the newly diagnosis of T2DM.